Abstract
Despite the demonstrated constitutive activation of NF-κB in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-κB, DHMEQ (which mainly blocks nuclear translocation of activated NF-κB) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G2/M cell cycle arrest and apoptosis, and downregulation of NF-κB target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-κB targeting in NPC implicates the importance of targeting this pathway in NPC.
Original language | English (US) |
---|---|
Pages (from-to) | 23-32 |
Number of pages | 10 |
Journal | Cancer Letters |
Volume | 287 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2010 |
Externally published | Yes |
Keywords
- Anti-invasion
- Anti-proliferation
- Apoptosis
- DHMEQ
- Nasopharyngeal carcinoma
- NF-κB inhibitor
ASJC Scopus subject areas
- Oncology
- Cancer Research